<DOC>
	<DOCNO>NCT00048711</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety , pharmacokinetics weekly intravenous infusion 1 mg/kg recombinant human N-acetylgalactosamine 4-sulfatase ( rhASB ) patient diagnose Mucopolysaccharidosis VI ( MPS VI )</brief_summary>
	<brief_title>Open-Label Study Efficacy Safety Recombinant Human N-acetylgalactosamine 4-sulfatase Patients With MPS VI</brief_title>
	<detailed_description />
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis VI</mesh_term>
	<criteria>Patient consent Patient must five year age old Patient must document biochemical genetic proof MPS VI Patient must walk least 1 meter , less 250 meter , first 6 minute baseline 12minute walk test If female childbearing potential , patient must negative pregnancy test Patient consideration undergone successful bone marrow transplant ( BMT ) . Pregnant lactating patient Patient receive investigational drug within 30 day prior study enrollment Patient previously treat rhASB Patient medical condition , serious intercurrent illness , extenuate circumstance may significantly confound study result decrease study compliance Patient know hypersensitivity rhASB component study drug History cancer ( except low grade fully resolve skin malignancy )</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>